TechnoPharmaSphere

Producing lipid nanoparticles (#LNPs) for RNA therapies has become more efficient and reliable than ever. With the introduction of a cutting-edge parallelized microfluidic device, LNP production now achieves unmatched consistency and scalability. This advancement is expected to significantly enhance the effectiveness of RNA-based treatments. The device employs advanced microfluidic mixing to precisely control LNP size and composition, improving both stability and delivery efficiency. A study published in 𝙉𝙖𝙣𝙤 𝙇𝙚𝙩𝙩𝙚𝙧𝙨 by Sarah J. Shepherd and her team at the University of Pennsylvania demonstrates how these techniques address a critical bottleneck in RNA therapeutic production, ensuring greater consistency and efficiency. ------------------------------------------------ 📌 Key highlights: 🔵 𝗣𝗿𝗼𝗱𝘂𝗰𝘁𝗶𝗼𝗻 𝗥𝗮𝘁𝗲 𝗜𝗻𝗰𝗿𝗲𝗮𝘀𝗲: The authors found that the parallelized microfluidic device (#PMD) achieved over a 100-𝙛𝙤𝙡𝙙 𝙞𝙣𝙘𝙧𝙚𝙖𝙨𝙚 in production rate (18.4 L/h) compared to traditional single-channel microfluidic devices. 🔵 𝗟𝗡𝗣 𝗦𝗶𝘇𝗲 𝗖𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻: The authors explored the size of LNPs and demonstrated that those formulated using microfluidic methods were consistently smaller than those produced by bulk mixing, with sizes less than 85 nm versus greater than 140 nm for bulk mixed LNPs. 🔵 𝗜𝗻 𝗩𝗶𝘃𝗼 𝗘𝗳𝗳𝗶𝗰𝗮𝗰𝘆: The authors demonstrated that LNPs encapsulating luciferase mRNA produced via the PMD resulted in a 5-fold increase in luciferase expression in mice compared to bulk mixed LNPs, indicating superior delivery and effectiveness. 🔵 𝗚𝗲𝗻𝗲 𝗦𝗶𝗹𝗲𝗻𝗰𝗶𝗻𝗴 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆: The authors found that Factor VII siRNA LNPs formulated with the PMD achieved over 90% reduction in Factor VII activity in plasma, while bulk mixed LNPs only reduced activity by about 20%. 🔵 𝗗𝗼𝘀𝗲 𝗢𝗽𝘁𝗶𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻: The authors explored dose optimization and selected a dose of 0.2 mg/kg of Factor VII siRNA LNPs based on initial studies, ensuring more than 50% knockdown of Factor VII activity in plasma at 48 hours post-injection. 🔵 𝗡𝗼 𝗦𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗧𝗼𝘅𝗶𝗰𝗶𝘁𝘆: The authors demonstrated through histological analysis of liver samples that there were no significant differences in toxicity between the different formulation groups, suggesting that the PMD method is safe for use. 🔵 𝗠𝗼𝗱𝘂𝗹𝗮𝗿 𝗗𝗲𝘀𝗶𝗴𝗻 𝗕𝗲𝗻𝗲𝗳𝗶𝘁𝘀: The authors highlighted the PMD's modular design, which allows for the incorporation of various mixing channel geometries, enhancing flexibility and scalability for future applications in LNP production. --------------------------------------------------------- How might this advancement influence the scalability of RNA therapeutics moving forward?🤔 #RNATherapeutics #LipidNanoparticles #LNPs #BiopharmaInnovation #Microfluidics #VaccineDevelopment #Innovation #Healthcare #Research #Pharmaceuticals

𝙒𝙝𝙖𝙩 𝙞𝙨 𝙩𝙝𝙚 𝙨𝙚𝙘𝙧𝙚𝙩 𝙗𝙚𝙝𝙞𝙣𝙙 𝙩𝙝𝙚 𝙨𝙪𝙘𝙘𝙚𝙨𝙨 𝙤𝙛 𝙍𝙉𝘼 𝙩𝙝𝙚𝙧𝙖𝙥𝙞𝙚𝙨?🤔 𝗧𝗵𝗲 𝘀𝗲𝗰𝗿𝗲𝘁 𝘀𝗮𝘂𝗰𝗲 𝗶𝘀 𝗶𝗼𝗻𝗶𝘇𝗮𝗯𝗹𝗲 𝗹𝗶𝗽𝗶𝗱𝘀! 💉 Before #Onpattro® was approved in 2018, scientists spent over a decade screening numerous ionizable lipids and LNP formulations. The success of #MC3 reignited interest in RNA delivery technologies. 🔍 During the pandemic, the importance of ionizable lipids became clear, as mRNA vaccines like Moderna 's mRNA-1273 and BioNTech SE 's BNT162b2 were developed at record speed, achieving over 94% efficacy. ⏱️💪 𝘞𝘩𝘢𝘵 𝘔𝘢𝘬𝘦𝘴 𝘐𝘰𝘯𝘪𝘻𝘢𝘣𝘭𝘦 𝘓𝘪𝘱𝘪𝘥𝘴 𝘚𝘱𝘦𝘤𝘪𝘢𝘭? ↳𝗩𝗲𝗿𝘀𝗮𝘁𝗶𝗹𝗲 𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲𝘀: Over 150 different ionizable lipids are currently under study, each with unique features like tertiary amines and branched tails, which enhance RNA delivery. 🧬 ↳𝗖𝗵𝗮𝗿𝗴𝗲 𝗔𝗱𝗮𝗽𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆: These lipids remain neutral in the bloodstream to reduce toxicity and become positively charged in acidic environments, which makes them effective for RNA release inside cells. ⚡ 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: 🔵 Alnylam Pharmaceuticals: Known for its pioneering work with Onpattro, Alnylam Pharmaceuticals has been a leader in RNAi therapeutics. 🔵 Pfizer /BioNTech SE and Moderna: These companies utilized ionizable lipids in their COVID-19 vaccines, showing the technology's potential. 🔵 Acuitas Therapeutics, Inc.: Specializes in developing lipid nanoparticle delivery systems, contributing significantly to the field with over 500 novel lipids. 🔹️These lipids are essential in developing new treatments, including CRISPR-Cas9 applications like NTLA-2001, which effectively reduces TTR levels in ATTR patients. 🧬🔬 ‐---------------------------------------------- What are your thoughts on the role of ionizable lipids in RNA therapies? Let’s discuss! 💬👇

👉 𝗜𝗺𝗮𝗴𝗶𝗻𝗲 𝗮 𝗳𝘂𝘁𝘂𝗿𝗲 𝘄𝗵𝗲𝗿𝗲 𝗥𝗡𝗔 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 𝗮𝗿𝗲 𝗻𝗼𝘁 𝗷𝘂𝘀𝘁 𝗮𝗱𝘃𝗮𝗻𝗰𝗲𝗱, 𝗯𝘂𝘁 𝘁𝗿𝘂𝗹𝘆 𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝘃𝗲—𝗺𝗼𝗿𝗲 𝗲𝗳𝗳𝗲𝗰𝘁𝗶𝘃𝗲, 𝗽𝗿𝗲𝗰𝗶𝘀𝗲, 𝗮𝗻𝗱 𝗮𝗳𝗳𝗼𝗿𝗱𝗮𝗯𝗹𝗲!💊 A recent study led by Bram Bogaert and his team at Ghent University, published in 𝘕𝘢𝘯𝘰 𝘓𝘦𝘵𝘵𝘦𝘳𝘴, is turning this vision into reality. By replacing cholesterol in lipid nanoparticles (#LNPs) with cationic amphiphilic drugs (#CADs), they're setting a new standard in biopharma innovation. 🔬 This research explores the novel use of CADs as a key component in LNPs, resulting in enhanced delivery of siRNA and mRNA. The findings demonstrate that these CAD-LNPs can effectively navigate biological barriers, such as mucus layers, and target epithelial and endothelial cells in a mouse model, all while maintaining a low pro-inflammatory response. 🧬🛡️ -------------------------------------------------------------- 𝗪𝗵𝘆 𝘁𝗵𝗶𝘀 𝗺𝗮𝘁𝘁𝗲𝗿𝘀: 🔗 𝘾𝘼𝘿 𝙄𝙣𝙩𝙚𝙜𝙧𝙖𝙩𝙞𝙤𝙣: The authors investigated the incorporation of cationic amphiphilic drugs (CADs) as a fifth component in lipid nanoparticles (LNPs), significantly enhancing their overall functionality. 📈 𝙄𝙢𝙥𝙧𝙤𝙫𝙚𝙙 𝙍𝙉𝘼 𝘿𝙚𝙡𝙞𝙫𝙚𝙧𝙮: Their findings revealed that partially substituting cholesterol in LNPs with CADs led to a remarkable increase in the cytosolic delivery of both siRNA and mRNA in human non-small cell lung carcinoma cells (H1299). 🧪 𝙀𝙥𝙞𝙩𝙝𝙚𝙡𝙞𝙖𝙡 𝙏𝙖𝙧𝙜𝙚𝙩𝙞𝙣𝙜: The research demonstrated that CAD-LNPs could successfully traverse the mucus layer in a human primary bronchial epithelial cell model after nebulization, showcasing their potential for respiratory therapies. 🌬️ 𝙀𝙣𝙝𝙖𝙣𝙘𝙚𝙙 𝙋𝙪𝙡𝙢𝙤𝙣𝙖𝙧𝙮 𝘿𝙚𝙡𝙞𝙫𝙚𝙧𝙮: Intranasal administration of MC3-NT and MC3-Fluox LNPs in mice resulted in significantly larger siRNA doses delivered to the pulmonary epithelium and endothelium compared to non-modified MC3-LNPs. 🛡️ 𝙇𝙤𝙬 𝙄𝙣𝙛𝙡𝙖𝙢𝙢𝙖𝙩𝙤𝙧𝙮 𝙍𝙚𝙨𝙥𝙤𝙣𝙨𝙚: The study found that CAD-LNPs did not trigger significant pro-inflammatory responses, indicating a favorable safety profile for therapeutic applications. 🔍 𝙂𝙧𝙖𝙙𝙪𝙖𝙡 𝘾𝘼𝘿 𝙇𝙚𝙖𝙠𝙖𝙜𝙚: The authors explored the gradual leakage of CAD during overnight dialysis, which may influence the molar lipid composition and biological performance of the LNPs. 💊 𝘿𝙧𝙪𝙜 𝘾𝙤𝙢𝙗𝙞𝙣𝙖𝙩𝙞𝙤𝙣 𝙏𝙝𝙚𝙧𝙖𝙥𝙮: They highlighted that the pharmacological activity of CADs was preserved after being incorporated into cholesterol-reduced CAD-LNPs, opening up possibilities for potential drug combination therapies. --------------------------------------------------------------- Want to learn more about the implications of CAD-LNPs for drug combination therapies? #Biopharma #RNATherapy #Innovation #LipidNanoparticles #LNPs #HealthcareRevolution

🐌 Don't let method variability slow you down! 🧪 🔵 TechnoPharmaSphere is your go-to partner for #GMP Analytical Method Development! 🔵 We understand the critical need for precision and consistency in your analytical methods, whether you're dealing with #compendial or customized approaches. 🔵 From the initial feasibility studies through rigorous verification, qualification, #validation, and seamless method transfer, we ensure your methods meet the highest GMP standards. 💎 Let us handle the complexities so you can focus on advancing your projects with confidence! ------------------------------------------------- ⏺ Contact us today to discuss your production process at a table with GMP experts! 📩 TechnoPharmaSphere 📧 [email protected] #lipidnanoparticles #LNP #nanoparticle #drugdiscovery #techtransfer #pharmaindustry #biotechnology #biopharmaceuticals #GMP #GLP

🔬 𝙒𝙝𝙖𝙩 𝙈𝙖𝙠𝙚𝙨 𝙇𝙞𝙥𝙞𝙙 𝙉𝙖𝙣𝙤𝙥𝙖𝙧𝙩𝙞𝙘𝙡𝙚𝙨 𝙩𝙝𝙚 𝙂𝙋𝙎 𝙤𝙛 𝘿𝙧𝙪𝙜 𝘿𝙚𝙡𝙞𝙫𝙚𝙧𝙮? 🗺️💊 The field of drug delivery is being transformed by the development of organ-specific lipid nanoparticles (#LNPs), which offer the potential to deliver therapeutic molecules directly to targeted organs. Here's a closer look at the different types of LNPs and their mechanisms: 🔵𝙄𝙤𝙣𝙞𝙯𝙖𝙗𝙡𝙚 𝙇𝙞𝙥𝙞𝙙 𝙉𝙖𝙣𝙤𝙥𝙖𝙧𝙩𝙞𝙘𝙡𝙚𝙨: These lipids change charge based on pH levels, helping condense nucleic acids like mRNA for efficient delivery. They are particularly effective in targeting the liver 🏥 due to their ability to facilitate endosomal escape in hepatocytes, making them ideal for liver-specific therapies. 🔵𝘾𝙖𝙩𝙞𝙤𝙣𝙞𝙘 𝙇𝙞𝙥𝙞𝙙 𝙉𝙖𝙣𝙤𝙥𝙖𝙧𝙩𝙞𝙘𝙡𝙚𝙨: Initially developed for gene delivery, these lipids have a permanent positive charge. While effective in binding nucleic acids, their use is limited by potential toxicity and short circulation times. They can be modified to target specific tissues and are often used in targeting the lungs 🌬️. 🔵𝘼𝙣𝙞𝙤𝙣𝙞𝙘 𝙇𝙞𝙥𝙞𝙙 𝙉𝙖𝙣𝙤𝙥𝙖𝙧𝙩𝙞𝙘𝙡𝙚𝙨: Although less common, anionic lipids aid in specific targeting strategies, offering a different approach to nanoparticle design. They can be tailored to influence biodistribution and are sometimes used to target organs like the spleen 🩸. A breakthrough in this field is the development of 𝗦𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲 𝗢𝗿𝗴𝗮𝗻 𝗧𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 (#SORT) Lipid Nanoparticles. By incorporating specific lipid components, SORT LNPs can direct therapies to particular organs, such as the liver, lungs, or spleen, through passive, active, and endogenous targeting mechanisms. This approach enhances delivery efficiency and reduces off-target effects, opening new possibilities for genetic therapies and protein replacement treatments 🚀. 💬 What are your thoughts on the potential of lipid nanoparticles in drug delivery? Share your insights in the comments below! 📚Sources: Wang et.al., Nature Protocols volume 18, 265–291 (2023) Zhou et. al. Exploration 2024;4:20210146. #LipidNanoparticles #LNPs #DrugDelivery #Biotechnology #PrecisionMedicine #Innovation

𝙒𝙝𝙖𝙩 𝙞𝙛 𝙬𝙚 𝙘𝙤𝙪𝙡𝙙 𝙙𝙚𝙡𝙞𝙫𝙚𝙧 𝙙𝙧𝙪𝙜𝙨 𝙬𝙞𝙩𝙝 𝙩𝙝𝙚 𝙥𝙧𝙚𝙘𝙞𝙨𝙞𝙤𝙣 𝙤𝙛 𝙖 𝙡𝙖𝙨𝙚𝙧?🤔 This is the exciting potential of microfluidics in nano-drug delivery systems! 🧬 Microfluidics is redefining drug delivery, offering precise control over nanoparticle properties and significant advantages over traditional methods. A recent study by Zhang Huan and colleagues highlights how microfluidics can enhance nano-drug delivery systems (#NDDS) by producing uniform particles with controlled size and shape, crucial for effective treatment outcomes. ------------------------------------------ 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 🔵 𝙀𝙣𝙝𝙖𝙣𝙘𝙚𝙙 𝘾𝙤𝙣𝙩𝙧𝙤𝙡: Microfluidics significantly improves the controllability and uniformity of NDDSs, allowing for precise tuning of physicochemical properties such as particle size, distribution, and morphology🔧 🔵 𝙉𝙖𝙧𝙧𝙤𝙬 𝙋𝙖𝙧𝙩𝙞𝙘𝙡𝙚 𝙎𝙞𝙯𝙚 𝘿𝙞𝙨𝙩𝙧𝙞𝙗𝙪𝙩𝙞𝙤𝙣: The technology enables the production of NDDSs with a narrow particle size distribution, which is crucial for consistent drug delivery and efficacy.📏 🔵 𝙃𝙞𝙜𝙝 𝘿𝙧𝙪𝙜-𝙇𝙤𝙖𝙙𝙞𝙣𝙜 𝘾𝙖𝙥𝙖𝙘𝙞𝙩𝙮: Microfluidics facilitates the creation of NDDSs with high drug-loading capacities, enhancing the therapeutic potential of the delivered drugs.💊 🔵 𝙄𝙢𝙥𝙧𝙤𝙫𝙚𝙙 𝙈𝙞𝙭𝙞𝙣𝙜 𝙀𝙛𝙛𝙞𝙘𝙞𝙚𝙣𝙘𝙮: The fast mixing and laminar flow properties in microfluidic systems lead to better mass transfer and reaction conditions, addressing issues of low mixing efficiency found in traditional methods.⚡ 🔵 𝘿𝙞𝙫𝙚𝙧𝙨𝙚 𝙉𝘿𝘿𝙎 𝙏𝙮𝙥𝙚𝙨: The article discusses various NDDSs synthesized using microfluidics, including liposomes, polymer nanoparticles, and inorganic nanoparticles, highlighting their potential in treating diseases like tumors, diabetes, and asthma.🔬 🔵 𝘾𝙝𝙖𝙡𝙡𝙚𝙣𝙜𝙚𝙨 𝙄𝙙𝙚𝙣𝙩𝙞𝙛𝙞𝙚𝙙: The review points out challenges in the current status of microfluidics-based NDDSs, including scalability, regulatory hurdles, and the need for standardized processes.⚠️ --------------------------------------- How do you see microfluidics influencing the future of drug delivery? #Microfluidics #NanoDrugDelivery #BiopharmaInnovation #FutureOfMedicine #HealthcareRevolution _________________________________________________________________________ 𝘋𝘰 𝘺𝘰𝘶 𝘭𝘪𝘬𝘦 𝘰𝘶𝘳 𝘚𝘯𝘪𝘱𝘱𝘦𝘵 𝘴𝘦𝘴𝘴𝘪𝘰𝘯𝘴? 𝘙𝘦𝘤𝘰𝘮𝘮𝘦𝘯𝘥, ♻ 𝘙𝘦𝘱𝘰𝘴𝘵, 𝘪𝘧 𝘺𝘰𝘶 𝘧𝘪𝘯𝘥 𝘪𝘵 𝘶𝘴𝘦𝘧𝘶𝘭.   TechnoPharmaSphere LLC. Biopharm Consultant and CRO https://lnkd.in/d_q6PUF https://lnkd.in/gy2zmS5m   ⏭ 𝘗.𝘚. 𝘚𝘵𝘢𝘺 𝘵𝘶𝘯𝘦𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘥𝘦𝘵𝘢𝘪𝘭𝘦𝘥 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘢𝘣𝘰𝘶𝘵 lipid nanoparticles 𝘢𝘯𝘥 𝘳𝘦𝘭𝘢𝘵𝘦𝘥 𝘤𝘰𝘯𝘵𝘦𝘯𝘵!

𝙒𝙝𝙖𝙩 𝙞𝙨 𝙩𝙝𝙚 𝙎𝙚𝙘𝙧𝙚𝙩 𝙎𝙖𝙪𝙘𝙚 𝙛𝙤𝙧 𝙀𝙛𝙛𝙚𝙘𝙩𝙞𝙫𝙚 𝙢𝙍𝙉𝘼 𝘿𝙚𝙡𝙞𝙫𝙚𝙧𝙮? The secret sauce of lipid nanoparticles (#LNPs) lies in their carefully selected lipid constituents. Understanding these components is crucial for advancing mRNA delivery technologies. But what makes these carriers so effective? A recent study in 𝘼𝘾𝙎 𝙉𝙖𝙣𝙤 uncovers the key lipid constituents that contribute to their success. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 𝙄𝙤𝙣𝙞𝙯𝙖𝙗𝙡𝙚 𝘾𝙖𝙩𝙞𝙤𝙣𝙞𝙘 𝙇𝙞𝙥𝙞𝙙𝙨: The authors found these lipids are crucial for mRNA escape from endosomes, becoming positively charged in acidic environments. They explored enzyme-catalyzed synthesis to optimize their performance. 𝙋𝙝𝙤𝙨𝙥𝙝𝙤𝙡𝙞𝙥𝙞𝙙𝙨: Serving as the backbone of LNPs, these lipids ensure stability. The authors used microfluidic mixing to refine their composition. 𝘾𝙝𝙤𝙡𝙚𝙨𝙩𝙚𝙧𝙤𝙡: This component enhances membrane fusion and stability. The study explored various cholesterol structures to improve delivery efficiency. 𝙋𝙀𝙂-𝙇𝙞𝙥𝙞𝙙𝙨: These lipids help LNPs evade the immune system, prolonging circulation time for more effective delivery. 𝙎𝙩𝙧𝙪𝙘𝙩𝙪𝙧𝙚-𝘼𝙘𝙩𝙞𝙫𝙞𝙩𝙮 𝙍𝙚𝙡𝙖𝙩𝙞𝙤𝙣𝙨𝙝𝙞𝙥𝙨: Understanding these relationships is vital for designing effective LNPs. Techniques like barcoding were utilized for high-throughput profiling. 𝙁𝙪𝙩𝙪𝙧𝙚 𝙋𝙧𝙤𝙨𝙥𝙚𝙘𝙩𝙨: The authors found potential for LNPs to target tissues beyond the liver, expanding therapeutic possibilities. ----------------------------------------------------- Check out the full article to discover how these insights can enhance your work in biopharma! #Biopharma #Innovation #LipidNanoparticles #LNPs #mRNA #DrugDelivery #GeneTherapy _________________________________________________________________________ 𝘋𝘰 𝘺𝘰𝘶 𝘭𝘪𝘬𝘦 𝘰𝘶𝘳 𝘚𝘯𝘪𝘱𝘱𝘦𝘵 𝘴𝘦𝘴𝘴𝘪𝘰𝘯𝘴? 𝘙𝘦𝘤𝘰𝘮𝘮𝘦𝘯𝘥, ♻ 𝘙𝘦𝘱𝘰𝘴𝘵, 𝘪𝘧 𝘺𝘰𝘶 𝘧𝘪𝘯𝘥 𝘪𝘵 𝘶𝘴𝘦𝘧𝘶𝘭.   TechnoPharmaSphere LLC. Biopharm Consultant and CRO https://lnkd.in/d_q6PUF https://lnkd.in/gy2zmS5m   ⏭ 𝘗.𝘚. 𝘚𝘵𝘢𝘺 𝘵𝘶𝘯𝘦𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘥𝘦𝘵𝘢𝘪𝘭𝘦𝘥 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘢𝘣𝘰𝘶𝘵 lipid nanoparticles 𝘢𝘯𝘥 𝘳𝘦𝘭𝘢𝘵𝘦𝘥 𝘤𝘰𝘯𝘵𝘦𝘯𝘵!

𝙒𝙝𝙖𝙩 𝙞𝙨 𝙩𝙝𝙚 𝙎𝙚𝙘𝙧𝙚𝙩 𝙎𝙖𝙪𝙘𝙚 𝙛𝙤𝙧 𝙀𝙛𝙛𝙚𝙘𝙩𝙞𝙫𝙚 𝙢𝙍𝙉𝘼 𝘿𝙚𝙡𝙞𝙫𝙚𝙧𝙮? The secret sauce of lipid nanoparticles (#LNPs) lies in their carefully selected lipid constituents. Understanding these components is crucial for advancing mRNA delivery technologies. But what makes these carriers so effective? A recent study in 𝘼𝘾𝙎 𝙉𝙖𝙣𝙤 uncovers the key lipid constituents that contribute to their success. 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: 𝙄𝙤𝙣𝙞𝙯𝙖𝙗𝙡𝙚 𝘾𝙖𝙩𝙞𝙤𝙣𝙞𝙘 𝙇𝙞𝙥𝙞𝙙𝙨: The authors found these lipids are crucial for mRNA escape from endosomes, becoming positively charged in acidic environments. They explored enzyme-catalyzed synthesis to optimize their performance. 𝙋𝙝𝙤𝙨𝙥𝙝𝙤𝙡𝙞𝙥𝙞𝙙𝙨: Serving as the backbone of LNPs, these lipids ensure stability. The authors used microfluidic mixing to refine their composition. 𝘾𝙝𝙤𝙡𝙚𝙨𝙩𝙚𝙧𝙤𝙡: This component enhances membrane fusion and stability. The study explored various cholesterol structures to improve delivery efficiency. 𝙋𝙀𝙂-𝙇𝙞𝙥𝙞𝙙𝙨: These lipids help LNPs evade the immune system, prolonging circulation time for more effective delivery. 𝙎𝙩𝙧𝙪𝙘𝙩𝙪𝙧𝙚-𝘼𝙘𝙩𝙞𝙫𝙞𝙩𝙮 𝙍𝙚𝙡𝙖𝙩𝙞𝙤𝙣𝙨𝙝𝙞𝙥𝙨: Understanding these relationships is vital for designing effective LNPs. Techniques like barcoding were utilized for high-throughput profiling. 𝙁𝙪𝙩𝙪𝙧𝙚 𝙋𝙧𝙤𝙨𝙥𝙚𝙘𝙩𝙨: The authors found potential for LNPs to target tissues beyond the liver, expanding therapeutic possibilities. ----------------------------------------------------- Check out the full article to discover how these insights can enhance your work in biopharma! #Biopharma #Innovation #LipidNanoparticles #LNPs #mRNA #DrugDelivery #GeneTherapy _________________________________________________________________________ 𝘋𝘰 𝘺𝘰𝘶 𝘭𝘪𝘬𝘦 𝘰𝘶𝘳 𝘚𝘯𝘪𝘱𝘱𝘦𝘵 𝘴𝘦𝘴𝘴𝘪𝘰𝘯𝘴? 𝘙𝘦𝘤𝘰𝘮𝘮𝘦𝘯𝘥, ♻ 𝘙𝘦𝘱𝘰𝘴𝘵, 𝘪𝘧 𝘺𝘰𝘶 𝘧𝘪𝘯𝘥 𝘪𝘵 𝘶𝘴𝘦𝘧𝘶𝘭.   TechnoPharmaSphere LLC. Biopharm Consultant and CRO https://lnkd.in/d_q6PUF https://lnkd.in/gy2zmS5m   ⏭ 𝘗.𝘚. 𝘚𝘵𝘢𝘺 𝘵𝘶𝘯𝘦𝘥 𝘧𝘰𝘳 𝘵𝘩𝘦 𝘥𝘦𝘵𝘢𝘪𝘭𝘦𝘥 𝘪𝘯𝘴𝘪𝘨𝘩𝘵𝘴 𝘢𝘣𝘰𝘶𝘵 lipid nanoparticles 𝘢𝘯𝘥 𝘳𝘦𝘭𝘢𝘵𝘦𝘥 𝘤𝘰𝘯𝘵𝘦𝘯𝘵!

❄️ 𝗘𝗻𝗵𝗮𝗻𝗰𝗶𝗻𝗴 𝗟𝗶𝗽𝗼𝘀𝗼𝗺𝗲 𝗦𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆: 𝗧𝗵𝗲 𝗥𝗼𝗹𝗲 𝗼𝗳 𝗖𝗿𝘆𝗼𝗽𝗿𝗼𝘁𝗲𝗰𝘁𝗮𝗻𝘁𝘀 ❄️ 🔵 Cryoprotectants (#CPAs) are vital in liposomal formulations, significantly boosting their stability and functional properties during and after freezing. These chemical agents lower the freezing point of water, acting much like "antifreeze" in other contexts. 🔵 Typically, a concentration of 5% to 15% cryoprotectant is sufficient to ensure a substantial portion of isolated cells survive freezing and thawing, even from liquid nitrogen temperatures. As temperatures drop, ice crystals form and squeeze cells into smaller pockets of unfrozen liquid. With cryoprotectants, these pockets are larger, reducing the risk of mechanical freezing injury and damage from high salt concentrations. 🔵 CPAs are categorized into two main types: membrane-permeating and non-membrane-permeating. 💠 𝗕𝘂𝘁 𝗵𝗲𝗿𝗲’𝘀 𝗮 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻: Which type of CPA do you find better suited for lab-scale liposome production? And what about large-scale manufacturing? 👇 Share your experiences below! 👇 #liposome #lipidnanoparticle #drugdelivery #drugdevelopment #biopharma #biotechnology #pharmaindustry 📑 Image source: Boafo, George Frimpong, et al. "The role of cryoprotective agents in liposome stabilization and preservation." International journal of molecular sciences 23.20 (2022): 12487.

𝘿𝙞𝙙 𝙮𝙤𝙪 𝙠𝙣𝙤𝙬 𝙩𝙝𝙖𝙩 𝙩𝙝𝙚 𝙧𝙞𝙜𝙝𝙩 𝙙𝙚𝙨𝙞𝙜𝙣 𝙥𝙖𝙧𝙖𝙢𝙚𝙩𝙚𝙧𝙨 𝙘𝙖𝙣 𝙚𝙣𝙝𝙖𝙣𝙘𝙚 𝙙𝙧𝙪𝙜 𝙙𝙚𝙡𝙞𝙫𝙚𝙧𝙮 𝙚𝙛𝙛𝙞𝙘𝙞𝙚𝙣𝙘𝙮? 🔬💊 Optimizing lipid nanoparticle (#LNP) formulations hinges on understanding and fine-tuning critical design parameters. Let's examine the key factors that influence LNP efficacy. 1️⃣ 𝗦𝗶𝘇𝗲 & 𝗣𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗖𝗼𝗻𝗰𝗲𝗻𝘁𝗿𝗮𝘁𝗶𝗼𝗻📏 ↳Optimal range: 50-200 nm ↳Key metric: Polydispersity Index (PDI) The size facilitates efficient cellular uptake while minimizing rapid clearance from the bloodstream. A low polydispersity index (#PDI) is crucial for uniformity in size, which can enhance the predictability of drug delivery. 2️⃣ 𝗠𝗼𝗿𝗽𝗵𝗼𝗹𝗼𝗴𝘆 🔷 ↳ Shapes include spherical, rod-like, star and even cubic or hexagonal structures ↳ Impacts cellular uptake and drug release Each morphology has a distinct impact on cellular uptake and drug release kinetics. For example, an exciting new research has introduced 𝗹𝗶𝗽𝗶𝗱 𝗻𝗮𝗻𝗼𝘀𝘁𝗮𝗿𝘀 (#LNSs), a novel star-shaped LNP variant. LNSs have shown 📈 cellular uptake and tumor accumulation compared to their spherical counterparts making morphology a vital consideration in formulation design. (https://lnkd.in/ehTj9fA6) 3️⃣ 𝗗𝗿𝘂𝗴 𝗘𝗻𝗰𝗮𝗽𝘀𝘂𝗹𝗮𝘁𝗶𝗼𝗻💊 Encapsulation efficiency is a crucial metric that indicates how much of the active drug is successfully loaded into the LNPs. Achieving an EE% greater than 90% is often a target for many applications, as higher efficiency can lead to better therapeutic outcomes and reduced side effects. 4️⃣ 𝗦𝘂𝗿𝗳𝗮𝗰𝗲 𝗣𝗿𝗼𝗽𝗲𝗿𝘁𝗶𝗲𝘀 🧪 ↳ Zeta potential: Typically ranging from -10 to +10 mV, it affects colloidal stability and cellular uptake. ↳ Surface modifications: PEGylation or the addition of targeting ligands can enhance circulation time and specificity. ↳ Surface charge: Positive charges often promote cellular uptake but may also increase non-specific interactions. --------------------------------------- These properties can make or break an LNP formulation. Interestingly, changes as small as 1% in lipid composition can significantly alter LNP behavior. Interested in learning more about the latest advancements in lipid nanoparticles? Follow our page for updates! 🔔 #Biopharma #DrugDelivery #LipidNanoparticles #LNPs